Related Experiment Video
Updated: Aug 11, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Medicare Part D drug benefit and HIV/AIDS: questions and answers
1University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Abstract:
This newly enacted legislation has the potential to expand access to needed medications for persons with HIV/AIDS and actually improve care by making medication more affordable. This is particularly true for patients who are currently enrolled in ADAPs with limited or restricted formularies. The benefit of the Part D program in states with more generous ADAP formularies, such as New York and California, is not as clear. Choosing a drug plan can also be complex. Providers and case managers should have knowledge of the plans that are offered in their areas. While a program such as this has the potential to improve access to drugs, providers should expect the unexpected, especially with a newly implemented program that is wide in scope and subject to change over time. In the end, we need to work to avoid interruptions in treatment for our patients.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Retrovirus Life Cycles
Drug Dosing: Geriatric Patients
Sexually Transmitted Infections
Pharmacokinetics: Drug–Drug Interactions
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

